Evidence map›Paper›PMID 31185273›Full record

ArticleMethods (San Diego, Calif.)2019

Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity.

Ian R Munhenzva, Connor W Barth, Martha Sibrian-Vazquez, Lei G Wang, Jorge O Escobedo, Summer L Gibbs, Robert M Strongin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods (San Diego, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.Proceedings of SPIE--the International Society for Optical Engineering · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ian R MunhenzvaDepartment of Chemistry, Portland State University, 1719 SW 10th Avenue, Portland, OR 97201, United States.
Connor W BarthBiomedical Engineering Department, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, OR 97239, United States.
Martha Sibrian-VazquezDepartment of Chemistry, Portland State University, 1719 SW 10th Avenue, Portland, OR 97201, United States.
Lei G WangBiomedical Engineering Department, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, OR 97239, United States.
Jorge O EscobedoDepartment of Chemistry, Portland State University, 1719 SW 10th Avenue, Portland, OR 97201, United States.
Summer L GibbsBiomedical Engineering Department, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, OR 97239, United States; Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, 2730 SW Moody Avenue, Portland, OR 97201, United States.
Robert M StronginDepartment of Chemistry, Portland State University, 1719 SW 10th Avenue, Portland, OR 97201, United States; OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, 2730 SW Moody Avenue, Portland, OR 97201, United States. Electronic address: strongin@pdx.edu.
Oregon Health & Science University · USPortland State University · US

Funding

A Simple and Robust Indicator for GlutathioneR15EB016870 · NIBIB · PORTLAND STATE UNIVERSITY · PI STRONGIN, ROBERT M · 2014 to 2014
$435k
NIBIB NIH HHS R15 EB016870
6 · The paper itself

Abstract

The current five-year survival rate of <5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalHumansMiceOptical ImagingPancreatic NeoplasmsBenzoxantheneFluorescence imagingFrozen sectionPancreatic cancerPanINPDACTumor targeting

Identifiers

PMID31185273
PMCPMC6851457
OpenAlexW2953302019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.